Philips reiterates FY25 outlook following steady Q3 performance
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
Glenmark will begin distribution in November 2025
The transaction is expected to be completed within one month from the signing of the definitive agreements.
Subscribe To Our Newsletter & Stay Updated